SCHEMBL12427064

SCHEMBL12427064

CCSc1nc(-c2ccccc2)ccc1CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 1/20 0.52
KDM4E B2RXH2 7/20 0.47
ALDH1A1 P00352 6/20 0.47
MAPT P10636 6/20 0.47
HPGD P15428 4/20 0.47
TDP1 Q9NUW8 4/20 0.47
HTT P42858 1/20 0.47
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 3/20 0.43
CLK1 P49759 1/20 0.43
GAA P10253 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
NOTUM Q6P988 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12427071 0.79 MAPT (0.46) KDM4EALDH1A1MAPTHPGDTDP1
SCHEMBL14931857 0.77 ALDH1A1 (0.58) SQORKDM4EALDH1A1MAPTHPGD
SCHEMBL14943937 0.75 ALDH1A1 (0.54) SQORKDM4EALDH1A1HPGDMEN1
SCHEMBL3210688 0.75 MEN1 (0.43) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL14932028 0.74 SQOR (0.48) SQORKDM4EALDH1A1MAPTHPGD
SCHEMBL12427066 0.72 HSD17B10 (0.50) SQORKDM4EALDH1A1MAPTHPGD
SCHEMBL2297589 0.71 HTR7 (0.64) SQORKDM4EALDH1A1MAPTHPGD
SCHEMBL10345265 0.71 GCGR (0.48) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL12427062 0.71 SQOR (0.53) SQORKDM4EALDH1A1MAPTHPGD
SCHEMBL22208283 0.69 SQOR (1.00) SQORKDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG SQOR 1609/4885KDM4E 3040/4885ALDH1A1 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.